Current Headlines

1. Cambrex Unveils $120 Million Investment To Expand API Manufacturing And Strengthen U.S. Drug Supply Resilience 10/22/2025

   Cambrex, a leading global CDMO, is addressing increased demand for API development and manufacturing and accelerating the company’s leadership role in the fast-growing peptide therapeutics market.

2. 7th Inflammasome Therapeutics Summit 10/21/2025

   Now in its 7th year, the Inflammasome Therapeutics Summit is the only industry forum focused exclusively on inflammasome-targeted drug development. Over three action-packed days, we will unpack high-impact case studies from the front lines – covering emerging upstream and downstream targets, mechanisms beyond canonical pathways, and how these insights are unlocking new disease areas from neuroinflammation and atopic dermatitis to obesity and fibrotic conditions.

3. New Discovery: Antipsychotic Drugs Could Inhibit Fungal Resistance Mechanisms 10/16/2025

   Invasive fungal infections have become a growing global health threat, claiming more than 6.5 million lives annually.

4. Indivi And Clouds Of Care Partner To Advance Deep Phenotyping In Early Alzheimer's And Parkinson's Drug Development 10/15/2025

   Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer’s and Parkinson’s disease.

5. Syngene International Invests In Dedicated Peptide Laboratory And Advanced Automation 10/15/2025

   Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster.

6. Chiesi Announces FDA Acceptance Of New Drug Application For Its Triple Combination Inhaler For The Maintenance Treatment Of Asthma 10/15/2025

   Chiesi USA, Inc. (key-A-zee), a biopharmaceutical company that supports patients in living their best possible lives through life-changing or lifesaving innovations, today announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application (NDA) for its investigational maintenance treatment of asthma in adults.

7. Leiden Researchers Pioneer 'Green' Framework For Sustainable Drug Development 10/14/2025

   Medical drugs are expensive to make and can have an adverse effect on the environment.

8. New Drug Combination To Tackle Advanced Prostate Cancer 10/14/2025

   Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research.

9. FDA Accepts Cingulate's New Drug Application For CTx-1301 In Attention-Deficit/Hyperactivity Disorder (ADHD) And Sets A May 31, 2026 PDUFA Date 10/14/2025

   Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), the company’s lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults.

10. Quotient Sciences And Biorasi Partner To Accelerate Early Phase Clinical Trials To Patient Proof-Of-Concept 10/14/2025

    Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO), today announced a strategic partnership to deliver fully integrated early phase clinical trial solutions.